Dexamethasone ophthalmic - Kiora Pharmaceuticals
Alternative Names: Dexamethasone phosphate; EGP-437Latest Information Update: 14 Jan 2022
At a glance
- Originator EyeGate Pharma
- Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
- Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dry eyes; Keratoplasty rejection; Ocular inflammation; Retinal disorders; Retinal oedema; Scleritis; Uveitis
Most Recent Events
- 08 Nov 2021 EyeGate Pharma is now called Kiora Pharmaceuticals
- 28 Apr 2019 No recent reports of development identified for phase-I development in Retinal-disorders in USA (Ophthalmic, Needle-free injection)
- 06 Sep 2018 Updated efficacy data from a phase III trial in Uveitis released by EyeGate Pharma